Moneycontrol PRO
Live: Market Live: Will Rally In Autos Hit A Speed Bump?

Buy Narayana Hrudayalaya; target of Rs 810: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Narayana Hrudayalaya has recommended buy rating on the stock with a target price of Rs 810 in its research report dated September 06, 2022.

September 07, 2022 / 01:27 PM IST
The research firm ICICI Securities believes earnings of apparel brands and retail companies under their coverage may surprise positively from Q3FY22E as the likely demand recovery may result in better than expected margin performance. Some of the costs savings achieved during pandemic may sustain and coupled with high operating leverage may lead to higher than pre-covid margins from Q3FY22E.  Stocks like Trent, V-Mart and Aditya Birla Fashion and Retail are the preferred picks backed by their strong and consistent track record of execution.

The research firm ICICI Securities believes earnings of apparel brands and retail companies under their coverage may surprise positively from Q3FY22E as the likely demand recovery may result in better than expected margin performance. Some of the costs savings achieved during pandemic may sustain and coupled with high operating leverage may lead to higher than pre-covid margins from Q3FY22E.  Stocks like Trent, V-Mart and Aditya Birla Fashion and Retail are the preferred picks backed by their strong and consistent track record of execution.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Prabhudas Lilladher's research report on Narayana Hrudayalaya


Narayana Hrudayalaya (NARH) recently signed an agreement with Shiva and Shiva Orthopaedic Hospital to acquire its 100 beds Orthopedic and Trauma Hospital in Bengaluru on slump sale basis for Rs2.8bn (Rs800mn to be recovered after 4 years). Though acquisition looks expensive, it will offer entire spectrum of services in Health City. We see limited impact on financials given small deal size, besides the said acquisition is in-line with guidance of Rs10bn capex as guided by mgmt. for FY23. We believe NARH’s aggressive capex plans in India along with Cayman operations over next 2-3 years will enhance growth visibility beyond FY24. Additionally, company’s ability to generate healthy margins/profitability in new Cayman unit will be a key monitorable. We are factoring $10mn EBITDA from Cayman’s new unit in FY24.



Outlook


Overall we expect EBITDA CAGR of 22% over FY22-FY24E and maintain ‘Buy’ rating at TP of Rs. 810/share, based on 20x FY24E EV/EBITDA for India business and 16x EV/EBITDA for Cayman hospitals. At CMP, the stock is trading at 16x EV/EBITDA (adj for IND AS) and 27x P/E on FY24E.


More Info

At 13:22 hrs Narayana Hrudayalaya was quoting at Rs 714.85, down Rs 0.90, or 0.13 percent.


It has touched an intraday high of Rs 724.80 and an intraday low of Rs 700.30.


It was trading with volumes of 10,143 shares, compared to its thirty day average of 17,825 shares, a decrease of -43.10 percent.


In the previous trading session, the share closed up 1.28 percent or Rs 9.05 at Rs 715.75.


The share touched its 52-week high Rs 775.00 and 52-week low Rs 492.10 on 05 April, 2022 and 21 October, 2021, respectively.


Currently, it is trading 7.76 percent below its 52-week high and 45.27 percent above its 52-week low.


Market capitalisation stands at Rs 14,608.73 crore.


For all recommendations report, click here


Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Narayana Hrudayalaya - 070922 - prabhu

Broker Research
first published: Sep 7, 2022 01:27 pm